ALSUntangled No. 16: Cannabis

References

• Kim K, Moore DH, Makriyannis A, Abood ME. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol 2006; 542(1–3):100–5.
   PubMedGoogle Scholar
• Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 2007; 101(1):87–98.
   PubMedGoogle Scholar
• Raman C, McAllister SD, Rizvi G, Patel SG, Moore DH, Abood ME. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5(1):33–9.
   PubMedGoogle Scholar
• Weydt P, Hong S, Witting A, Möller T, Stella N, Kliot M. Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6(3):182–4.
   PubMedGoogle Scholar
• Rossi S, De Chiara V, Musella A, Cozzolino M, Bernardi G, Maccarrone M, Mercuri NB, Carri MT, Centonze D. Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009; 19:1–8.
   Google Scholar
• Bilsland LG, Dick JR, Pryce G, Petrosino S, Di Marzo V, Baker D, Greensmith L. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J 2006; 20(7):1003–5.
   PubMedGoogle Scholar
• Bilsland LG, Greensmith L. The endocannabinoid system in amyotrophic lateral sclerosis. Curr Pharm Des 2008; 14(23): 2306–16.
   PubMedGoogle Scholar
• Zhao P, Ignacio S, Beattie EC, Abood ME. Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity. Eur J Neurosci 2008; 27(3):572–9.
   PubMedGoogle Scholar
• Witting A, Weydt P, Hong S, Kliot M, Moller T, Stella N. Endocannabinoids accumulate in spinal cord of SOD1 transgenic mice. J Neurochem. 2004;89:1555–7.
   PubMed Web of Science ®Google Scholar
• Carter GT, BS Rosen. Marijuana in the management of amyotrophic lateral sclerosis. Am J Hosp Palliat Care 2001; 18(4):264–70.
   PubMedGoogle Scholar
• Gelinas D, Miller RG, Abood ME. A pilot study of safety and tolerability of Delta 9-THC (Marinol) treatment for ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3(Suppl. 1):23.
   PubMed Web of Science ®Google Scholar
• Amtmann D, Weydt P, Johnson KL, Jensen MP, Carter GT. Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care. 2004;21:95–104.
   PubMedGoogle Scholar
• Carter GT, Weydt P. Cannabis: old medicine with new promise for neurological disorders. Curr Opin Investig Drugs 2002; 3(3):437–440
   PubMedGoogle Scholar
• Gerra G, Zaimovic A, Gerra ML, Ciccocioppo R, Cippitelli A, Serpelloni G, Somaini L. Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists. Recent Pat CNS Drug Discov 2010; 5(1):46–52.
   PubMedGoogle Scholar
• Fischedick JT, Glas R, Hazekamp A, Verpoorte R. A qualitative and quantitative HPTLC densitometry method for the analysis of cannabinoids in Cannabis sativa L. Phytochem Anal 2009; 20(5):421–6.
   PubMedGoogle Scholar
• Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009; 30(10):515–27.
   PubMedGoogle Scholar
• Hill AJ, Williams CM, Whalley BJ, Stephens GJ. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther 2012;133:79–97.
   PubMed Web of Science ®Google Scholar
• Akinshola BE; Chakrabarti A; Onaivi ES. In vitro and in vivo action of cannabinoids. Neurochem Res 1999; 24(10): 1233–40.
   PubMedGoogle Scholar
• Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, and Hollister, L. Pharmacokinetics and metabolism of delta 1 tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 1986; 38(1):21–43.
   PubMedGoogle Scholar
• Borrelli F, Aviello G, Romano B, Orlando P, Capasso R, Maiello F, Guadagno F, Petrosino S, Capasso F, Di Marzo V, Izzo AA. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med 2009; 87(11):1111–21.
   PubMedGoogle Scholar
• Zanelati TV, Biojone C, Moreira FA, Guimarães FS, Joca SR. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol 2010; 159(1):122–8.
   PubMedGoogle Scholar
• Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, Whalley BJ, Stephens GJ. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther 2010;332(2):569–77.
   PubMedGoogle Scholar
• Abood ME. Molecular biology of cannabinoid receptors. Handb Exp Pharmacol 2005; 168:81–115.
   Google Scholar
• McAllister SD, Hurst DP, Barnett-Norris J, Lynch D, Reggio PH, Abood ME, Structural mimicry in class AG protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J Biol Chem 2004; 279(46):48024–37.
   PubMedGoogle Scholar
• McAllister SD, Chan C, Taft RJ, Luu T, Abood ME, Moore DH, Aldape K, Yount G, Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. J Neurooncol 2005; 74(1): 31–40
   PubMedGoogle Scholar
• Kapur A, Samaniego P, Thakur GA, Makriyannis A, Abood ME. Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction. J Pharmacol Exp Ther 2008; 325(1):341–8.
   PubMedGoogle Scholar
• Gehani NC, Nalwalk JW, Razdan RK, Martin BR, Sun X, Wentland M, Abood ME, Hough LB. Significance of cannabinoid CB1 receptors in improgan antinociception. J Pain 2007; 8(11):850–60.
   PubMedGoogle Scholar
• Anavi-Goffer S, Fleischer D, Hurst DP, Lynch DL, Barnett-Norris J, Shi S, Lewis DL, Mukhopadhyay S, Howlett AC, Reggio PH, Abood ME, Helix 8 Leu in the CB1 cannabinoid receptor contributes to selective signal transduction mechanisms. J Biol Chem 2007; 282(34):25100–13.
   PubMedGoogle Scholar
• McAllister SD, Rizvi G, Anavi-Goffer S, Hurst DP, Barnett-Norris J, Lynch DL, Reggio PH, Abood ME, An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. J Med Chem 2003; 46:24:5139–52.
   PubMed Web of Science ®Google Scholar
• McAllister SD, Tao Q, Barnett-Norris J, Buehner K, Hurst DP, Guarnieri F, Reggio PH, Nowell Harmon KW, Cabral GA, Abood ME, A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition. Biochem Pharmacol 2002; 63(12):2121–36.
   PubMedGoogle Scholar
• Abood ME, Rizvi G, Sallapudi N, McAllister SD, Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci Lett 2001; 309(3):197–201.
   PubMedGoogle Scholar
• Panikashvili D, Simeonidou C, Ben Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E. An endogenous cannabinoid (2 AG) is neuroprotective after brain injury. Nature 2001; 4;413(6855):527–31.
   Google Scholar
• Chen Y; Buck J. Cannabinoids protect cells from oxidative cell death: a receptor independent mechanism. J Pharmacol Exp Ther 2000 Jun;293(3):807–12.
   PubMedGoogle Scholar
• Eshhar N; Striem S; Biegon A. HU 211, a non psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. Neuroreport 1993 13;5(3):237–40.
   Google Scholar
• Guzman M, Sanchez C, Galve-Roperth I. Control of the cell survival/death decision by cannabinoids. J Mol Med 2001; 78:613–625.
   PubMed Web of Science ®Google Scholar
• Maenpaa H, Mannerstrom M, Toimela T, Salminen L, Saransaari P, Tahti H. Glutamate uptake is inhibited by tamoxifen and toremifene in cultured retinal pigment epithelial cells. Pharmacol Toxicol 2002; 91(3):116–122
   PubMedGoogle Scholar
• Klein TW; Lane B; Newton CA; Friedman H. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 2000;225(1):1 8.
   PubMedGoogle Scholar
• Pertwee RG: Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin Investig Drugs 2000;9(7):1553–71.
   PubMedGoogle Scholar
• Akinshola BE; Chakrabarti A; Onaivi ESIn vitro and in vivo action of cannabinoids. Neurochem Res 1999;24(10): 1233–40
   PubMedGoogle Scholar
• Di Marzo, Bisogno T, De Petrocellis L. Endocannabinoids: new targets for drug development. Curr Pharm Des 2000; 6(13):1361–80.
   PubMedGoogle Scholar
• Hanuš LO, Mechoulam R. Novel Natural and Synthetic Ligands of the Endocannabinoid System. Curr Med Chem 2010; Feb 18. [Epub ahead of print].
   PubMedGoogle Scholar
• De Laurentiis A, Fernández Solari J, Mohn C, Zorrilla Zubilete M, Rettori V. Endocannabinoid system participates in neuroendocrine control of homeostasis. Neuroimmunomodulation 2010;17(3):153–6.
   PubMedGoogle Scholar
• Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem 2009;1(7):1333–1349.
   PubMedGoogle Scholar
• Mouslech Z, Valla V. Endocannabinoid system: An overview of its potential in current medical practice. Neuro Endocrinol Lett 2009;30(2):153–79.
   PubMedGoogle Scholar
• Wegener N, Koch M. Neurobiology and systems physiology of the endocannabinoid system. Pharmacopsychiatry 2009;42 Suppl 1:S79–86.
   PubMedGoogle Scholar
• De Petrocellis L, Di Marzo V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab 2009;23(1):1–15.
   PubMedGoogle Scholar
• Goodfellow CE, Glass M. Anandamide receptor signal transduction. Vitam Horm. 2009;81:79–110.
   PubMedGoogle Scholar
• Pertwee RG. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 2008;13(2):147–59.
   PubMed Web of Science ®Google Scholar
• Cencioni MT, Chiurchiù V, Catanzaro G, Borsellino G, Bernardi G, Battistini L, Maccarrone M. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One 2010; 5(1):e8688.
   Google Scholar
• Pasquariello N, Catanzaro G, Marzano V, Amadio D, Barcaroli D, Oddi S, Federici G, Urbani A, Finazzi Agrò A, Maccarrone M. Characterization of the endocannabinoid system in human neuronal cells and proteomic analysis of anandamide-induced apoptosis. J Biol Chem 2009 23;284(43): 29413–26.
   Google Scholar
• Pandey R, Mousawy K, Nagarkatti M, Nagarkatti P. Endocannabinoids and immune regulation. Pharmacol Res> 2009; 60(2):85–92.
   PubMedGoogle Scholar
• Parolaro D, Massi P, Rubino T, Monti E. Endocannabinoids in the immune system and cancer. Prostaglandins Leukot Essent Fatty Acids 2002; 66(2–3):319–32.
   PubMedGoogle Scholar
• Papadimitriou D, Le Verche V, Jacqier A, Ikiz B, Przedborski S, Re DB. Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiol Dise 2010:37:493–502.
   PubMed Web of Science ®Google Scholar
• Appel SH, Zhao W, Beers DR, Henkel JS. The microglial-motoneuron dialogue in ALS. Acta Myol 2011;30:4–8.
   PubMedGoogle Scholar
• Maenpaa H, Mannerstrom M, Toimela T, Salminen L, Saransaari P, Tahti H. Glutamate uptake is inhibited by tamoxifen and toremifene in cultured retinal pigment epithelial cells. Pharmacol Toxicol 2002; 91(3):116–122
   PubMedGoogle Scholar
• Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, Fagan SC, Cudkowicz ME. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 2006; 11; 67(1):20–7.
   Google Scholar
• Lee ES, Yin Z, Milatovic D, Jiang H, Aschner M. Estrogen and tamoxifen protect against Mn-induced toxicity in rat cortical primary cultures of neurons and astrocytes. Toxicol Sci 2009;110(1):156–67.
   PubMedGoogle Scholar
• Raman C, McAllister SD, Rizvi G, Patel SG, Moore DH, Abood ME. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Latearl Scler Other Motor Neuron Disor 2004;5:33–39.
   PubMed Web of Science ®Google Scholar
• Weber M, Goldman B, Truniger S. Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomized, double-blind crossover trial. J Neurol Neurosurg Psychiatry 2010;1135–40.
   PubMedGoogle Scholar
• Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, Banati RR, Anand P. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 2006; 6:12.
   PubMed Web of Science ®Google Scholar
• Hampson AJ; Grimaldi M; Axelrod J; Wink D. Cannabidiol and( )Delta9 tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 95(14):8268 73, 1998.
   Google Scholar
• Hampson AJ; Grimaldi M; Lolic M; Wink D; Rosenthal R; Axelrod J: Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci 899:274 82, 2000.
   PubMedGoogle Scholar
• Nagayama T; Sinor AD; Simon RP; Chen J; Graham SH; Jin K; Greenberg DA. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19(8):2987 95, 1999.
   Google Scholar
• Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007;4(8):1614–48.
   PubMedGoogle Scholar
• El Sohly MA, Wachtel SR, de Wit H. Cannabis versus THC: response to Russo and McPartland. Psychopharmacology 2003; 165(4):433–434.
   Google Scholar
• Carter GT, Flanagan A, Earleywine M, Abrams DI, Aggarwal SK, Grinspoon L: Cannabis in palliative medicine: improving care and reducing opioid-related morbidity. Am J Hosp Palliat Med 2011; 28(5):297–303
   PubMedGoogle Scholar
• Aggarwal SK, Carter GT, Sullivan MD, Morrill R, ZumBrunnen C, Mayer JD. Characteristics of patients with chronic pain accessing treatment with medicinal cannabis in Washington State. J Opioid Manag 2009; 5(5):257–286
   PubMedGoogle Scholar
• Carter GT, Abood ME, Aggarwal SK, Weiss MD. Cannabis and amyotrophic lateral sclerosis: practical and hypothetical applications, and a call for clinical trials. Am J Hosp Palliat Med 2010; 27(5):347–56;
   PubMedGoogle Scholar
• Carter GT, Weydt P, Kyashna-Tocha M, Abrams DI. Medicinal cannabis: rational guidelines for dosing. IDrugs 2004;7(5):464–70.
   PubMedGoogle Scholar
• Aggarwal SK, Kyashna-Tocha M, Carter GT. Dosing Medical Marijuana: Rational Guidelines on Trial in Washington State. MedGenMed 2007; 9(3):52–3.
   PubMedGoogle Scholar
• Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther 2007; 82(5): 572–8.
   PubMedGoogle Scholar
• Pomahacova B, Van der Kooy F, Verpoorte R. Cannabis smoke condensate III: The cannabinoid content of vaporised Cannabis sativa. Inhal Toxicol 2009;21(13):1108–12.
   PubMedGoogle Scholar
• Kmietowicz Z. Cannabis based drug is licensed for spasticity in patients with MS. BMJ 2010;340:c3363.
   Google Scholar